Background: Anti-angiogenic agents are now being clinically evaluated for the treatment of pancreatic cancer and a detailed investigation of the angiogenic profile of pancreatic cancer is needed. The aim of this study was to evaluate the plasma concentrations of angiogenesisrelated molecules in patients with pancreatic cancer, compared with those with other diseases. Methods: Plasma samples obtained from 45 patients with pancreatic cancer were analyzed and compared with those from 9 patients with pancreatitis, 16 patients with benign hepatobiliary diseases and 58 patients with colorectal cancers. The plasma levels of angiogenesisrelated molecules including angiopoietin-2, follistatin, granulocyte-colony stimulating factor, hepatocyte growth factor, interleukin-8, leptin, platelet-derived growth factor beta polypeptide, platelet endothelial cell adhesion molecule-1 and vascular endothelial growth factor were determined using an antibody suspension bead arrays system. Results: The plasma levels of all the angiogenesis-related molecules were not increased in patients with pancreatic cancer, compared with those with pancreatitis and benign hepatobiliary diseases, whereas the levels of those with colorectal cancer were markedly increased. The plasma interleukin-8 concentration was significantly elevated in patients with distant metastases and was associated with a poor treatment outcome of chemotherapy in patients with pancreatic cancer. Conclusions: The plasma levels of angiogenesis-related molecules were not elevated in patients with pancreatic cancer, compared with those with benign diseases or colorectal cancer. The plasma interleukin-8 level may be a novel biomarker for the response to chemotherapy in patients with pancreatic cancer and warrants further prospective study.
INTRODUCTION
Pancreatic cancer (PC) is a highly metastatic and biologically aggressive malignancy that is the fourth leading cause of death from cancer, with an overall 5-year survival rate of 6% and a median survival period of ,6 months (1). The only potential cure is surgery. However, since the diagnosis of PC is often established at an advanced stage, ,20% of patients diagnosed with this disease are suitable candidates for surgical resection.
Tumor angiogenesis, the process of new blood vessel formation, is considered to be an important mechanism for solid tumors to proliferate and metastasize beyond the limits of passive diffusion ( 2 -3 mm 3 ) in the setting of tumor growth (2) . The balance between pro-and anti-angiogenic factors is shifted to enable the sustained production of pro-angiogenic factors, leading to the production of new blood vessels that support the tumor. Angiogenesis is crucial for the proliferation and metastasis of solid tumors, including PC (3) . To date, anti-angiogenic agents are widely used for standard treatment in colorectal cancer (CC), renal cell carcinoma and hepatocellular carcinoma and are now considered to be well-validated targets for cancer treatment (4) . Especially, vascular endothelial growth factor (VEGF)-targeted therapy has become important for the systemic treatment of several solid tumors. Therefore, anti-angiogenic agents are currently under extensive investigation as novel approaches to the management of PC. Although a monoclonal antibody to VEGF and axitinib, a small-molecule tyrosine-kinase inhibitor, have yielded promising response rates in some phase II studies, they have not been shown to prolong survival when added to chemotherapy in any randomized phase III trials for patients with PC (5 -8). Angiogenesis-targeted therapy is now under clinical evaluation in patients with PC; therefore, a detailed investigation of the angiogenic profile of PC is needed.
The imaging findings of PC are commonly believed to reveal hypo-vascular tumors; however, several studies have shown an association between elevated VEGF expression and the intra-tumoral microvessel density (9, 10) , an increased size and the enhanced local spreading of the tumor (9), the presence of liver metastases and a poor prognosis in patients with PC (11 -13). Meanwhile, plasma or serum angiogenesisrelated molecules, including both pro-and anti-angiogenic factors, are expected to be biomarkers of tumor-related angiogenesis. Some studies have shown that a high level of circulating VEGF can be used as a prognostic factor in patients with PC (14, 15) . To date, however, no data on angiogenesisrelated molecules in patients with PC compared with those in patients with other cancers or benign pancreatic disease or the simultaneous measurement of multiplex factors have been reported. Thus, the angiogenic profile remains unclear in patients with PC, and such data may be useful for introducing anti-angiogenic therapy for the treatment of PC. We previously showed that the antibody suspension bead arrays system was a powerful tool for screening biomarkers in a clinical setting (16) In this study, we measured the plasma levels of angiogenesis-related factors in patients with PC and then evaluated the correlations between these levels and the clinical characteristics of patients with PC.
PATIENTS AND METHODS

PATIENTS
A total of 45 patients diagnosed as having PC at the Kinki University Hospital, Osaka, Japan, between April 2007 and March 2009 were enrolled. The patients' characteristics are shown in Table 1 . The diagnosis of PC was confirmed by histopathological examination of a resected tumor, biopsy or cytology specimen. The staging of the PC was determined according to the TNM classification. The clinical features of the patients, including age, sex, tumor location and size, TNM staging, presence of distant metastasis, performance status (PS), CRP, carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and treatment were recorded. Among the 23 patients who received chemotherapy (10 with gemcitabine alone, 5 with TS-1 alone and 8 with a combination of gemcitabine and TS-1), the response to chemotherapy, the progression-free survival time and the overall survival time were recorded. The tumor response was evaluated at a month after the start of therapy and every 2 months thereafter using computerized tomography according to the Blood samples were collected before the initial treatments. Four milliliters of peripheral venous blood was drawn into a tube containing ethylenediaminetetraacetic acid (EDTA) and immediately prepared by centrifugation at Â1200 g for 10 min. Plasma samples were removed and stored at 2808C until use.
MEASUREMENT OF ANGIOGENESIS-RELATED FACTORS IN PLASMA
The plasma concentrations of angiogenesis-related factors were measured using an antibody suspension bead array, Bio-Plex Pro TM Assays and Human Angiogenesis 9-Plex Panel (Bio-Rad Laboratories, Hercules, CA). The molecules used in this panel were as follows: angiopoietin-2, follistatin, granulocyte-colony stimulating factor (G-CSF), hepatocyte growth factor (HGF), interleukin-8 (IL-8), leptin, plateletderived growth factor beta polypeptide (PDGF-BB), platelet endothelial cell adhesion molecule-1 (PECAM-1) and VEGF. Data were obtained using a Bio-Plex suspension array systemw (Bio-Rad Laboratories, Hercules, CA). The assay was performed according to the manufacturer's instructions and a previously described method (16, 17) . Plasma samples were diluted 1 in 4 with the appropriate diluents prior to assay. The samples were tested in duplicate and the averages were used for analysis.
STATISTICAL ANALYSIS
The plasma levels of each angiogenesis-related molecule were summarized as the mean and standard deviation and then compared between the group of patients with PC and the group with CC, pancreatitis or benign hepatobiliary disease using the Mann -Whitney test. In a group of patients with PC, the plasma levels were compared across subgroups of patients on the basis of age ( 60 years vs. .60 years), sex, tumor location (head vs. body or tail), tumor size ( 20 mm vs. .20 mm), TNM stage (I, II vs. III, IV), lymph node metastasis status and distant metastasis status using the Mann -Whitney test. The analyses for survival time [ progression-free survival (PFS) and overall survival (OS)] were performed in the group of patients who received chemotherapy. In terms of the analysis for survival time, clinical factors including age ( 60 years vs. .60 years), sex, tumor size ( 20 mm vs. .20 mm), TNM stage (I, II vs. III, IV), lymph node metastasis status, distant metastasis status, PS, CRP, CEA, CA19-9 and the plasma levels of each angiogenesis-related factor were examined using the Cox proportional hazards model. The survival distributions for PFS and OS were estimated using the Kaplan -Meier method. The differences between two groups were compared using the log-rank test. A P value ,0.05 was considered statistically significant. Data analyses were performed using IBM w SPSS w Statistics 19 software (IBM Corporation, Somers, NY).
RESULTS
PATIENT CHARACTERISTICS
A total of 45 patients with PC, 9 patients with pancreatitis, 16 patients with benign hepatobiliary diseases and 58 patients with TNM stage-matched CCs were enrolled in this study ( Table 1 ). The patients with PC ranged in age from 39 to 81 years, with a median of 69 years and the male:female ratio was 16:29. The TNM stages of the patients with PC were as follows: stage I, 5; stage II, 2; stage III, 22 and stage IV, 16. Among the patients with PC, 10 patients received surgery, 4 received best supportive care and 31 received chemotherapy. The clinical data for 8 patients who received chemotherapy was missing, so 23 patients receiving chemotherapy were analyzed.
PLASMA CONCENTRATIONS OF ANGIOGENESIS-RELATED MOLECULES AMONG PATIENTS WITH PC COMPARED WITH THOSE WITH CC, PANCREATITIS OR BENIGN HEPATOBILIARY DISEASE
The plasma concentrations of angiogenesis-related molecules are shown in Fig. 1 . The plasma concentrations of all the molecules could be determined in all the samples except for two samples in which the leptin concentrations were below the detectable limit. The levels of G-CSF, HGF, IL-8, leptin, PECAM-1 and VEGF in the patients with PC were significantly lower than those in the patients with colon cancer. The plasma concentration of follistatin in patients with PC was significantly higher than that in patients with colon cancer. Compared with the patients with benign diseases, the concentrations of follistatin, HGF and VEGF in the patients with PC were significantly lower than those in the patients with either pancreatitis or benign hepatobiliary disease, while the leptin level was lower than that in patients with benign hepatobiliary disease. These results clearly indicated that the concentrations of most angiogenesis-related molecules were not elevated in patients with PC but were elevated in patients with CC.
CORRELATION BETWEEN ANGIOGENESIS-RELATED MOLECULES AND THE CLINICAL FEATURES OF ALL THE PC PATIENTS
Next, we evaluated the correlation between the plasma concentrations of angiogenesis-related molecules and clinical features including age, sex, tumor location, tumor size, TNM stage, lymph node metastasis and distant metastasis in all the patients with PC (Table 2) . Although the reason remains unknown, the plasma concentrations of HGF and PECAM were significantly elevated in the older age group. Regarding distant metastasis, the plasma IL-8 level was significantly higher in the metastasis-positive group than in the metastasis-negative group (P ¼ 0.024, Fig. 2, Table 2 ). The HGF and angiopoietin-2 levels tended to be higher in the metastasis-positive group, but the differences were not significant (P ¼ 0.073 and P ¼ 0.073).
UNIVARIATE ANALYSIS OF CLINICAL BIOMARKERS FOR PFS AND OS
To find biomarkers for the response to chemotherapy among patients with PC, clinical molecular factors were evaluated according to treatment outcome among chemotherapy-treated patients with PC (Table 3 ). The CRP, CEA and CA19-9 levels were significantly associated with PFS (P ¼ 0.026, 0.015 and 0.017, respectively), and the CEA and CA19-9 Figure 1 . Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer, colon cancer, pancreatitis or hepatobiliary disease. The differences in the follistatin, hepatocyte growth factor (HGF), leptin and vascular endothelial growth factor (VEGF) levels between the pancreatic cancer group and the other groups were statistically significant (*P , 0.05). The top and bottom quartiles and the median values are depicted as box plots. levels were significantly associated with OS (P ¼ 0.003 and 0.012, respectively). The TNM stages tended to be a poor prognostic factor, but the relation was not significant (P ¼ 0.065 and P ¼ 0.177), presumably because of the small number of samples. Of note, the plasma IL-8 level was significantly associated with the PFS and OS (P ¼ 0.039 and P ¼ 0.01). Figure 3 shows the Kaplan -Meier estimates for PFS and OS with regard to the concentrations of plasma IL-8. Although the determination of an optimal cutoff value was beyond the scope of this study, all the patients were divided into two groups according to the median value (29.0 pg/ml). The median PFS of the high IL-8 group was 240 days (95% CI: not reached 2504.3) and that of the low IL-8 group was 331 days (95% CI: 176.5 -485.5), showing a significantly shorter PFS for the patients in the high IL-8 group (P ¼ 0.025, log-rank test). The median OS of the high IL-8 group was 481 days (95% CI: not reached 2971.9) and that of the low IL-8 group was 542 days (95% CI: 482.6 -601.4), showing a tendency toward a shorter OS for the high IL-8 Figure 2 . The plasma interleukin-8 (IL-8) was significantly higher among patients with metastasis than those without metastasis in patients with pancreatic cancer. The median IL-8 levels in patients with metastasis and without metastasis were 41.6 pg/ml (range, 21.2 -106.5 pg/ml) and 26.8 pg/ ml (range, 7.9 -171.6 pg/ml), respectively. The top and bottom quartiles and the median values are depicted as box-plots. group, although the trend was not significant (P ¼ 0.108, log-rank test) (Fig. 3B) . These results indicate that a high plasma IL-8 level is associated with a poor treatment outcome among patients with PC who were treated with chemotherapy.
DISCUSSION
We analyzed the plasma levels of multiple angiogenesisrelated molecules in patients with PC using the antibody suspension bead arrays system. All the molecules were simultaneously measured using a 15-ml volume of sample plasma. Since biopsies for PC are usually invasive, our approach is to find plasma biomarkers that can be safely and repeatedly used. Some studies have shown that the plasma concentrations of HGF, IL-8 and VEGF are significantly higher among PC patients than among healthy controls (18 -20) . Unexpectedly, we found that the plasma levels of angiogenesis-related molecules were not increased in patients with PC but were increased in patients with CC. Although we did not have any data on healthy controls, we directly compared the plasma levels of angiogenesis-related molecules in patients with PC and those with benign diseases or CC; the results suggested that the involvement of angiogenesis is smaller in PC than it is in CC. In CCs, the VEGF monoclonal antibody bevacizumab has been shown to provide a significant clinical benefit when added to chemotherapy, and this agent is already widely used for standard therapy. On the other hand, no active anti-angiogenic agents have been established for the treatment of PC. These clinical differences in anti-angiogenic agents may be explained by the absence of increased angiogenesis-related molecules in PC and the increased presence of these molecules in CC. However, the levels of VEGF and HGF were clearly increased in a partial subpopulation of patients with PC, but not in all patients (Fig. 1) , suggesting that patient selection using effective biomarkers for antiangiogenic therapy may be useful and necessary for the introduction of anti-angiogenic therapy to the treatment of PC.
IL-8, a member of the CXC chemokine family, is one of the major mediators of the inflammatory response (21) . In cancer cells, secretion of IL-8 from cancer cells can enhance the proliferation and survival of cancer cells through autocrine signaling pathways (22) . In addition, tumor-derived IL-8 will activate endothelial cells in the tumor vasculature to promote angiogenesis and induce a chemotactic infiltration of neutrophil into the tumor site (22) . We examined the protein expression levels of IL-8 against a pair of sample-available primary and metastatic PC tumor tissues using immunohistochemistry. Immunohistochemical studies showed that cytoplasmic IL-8 expression was observed in a part of primary and metastatic tumor cells. IL-8 expressing cell numbers are likely to be increased in metastatic tumor, although further analysis is necessary (Supplementary data, Fig. S1 ). In PC, IL-8 is linked to tumor progression through its regulation of angiogenesis and the expression level of IL-8 appears to be correlated with the tumorigenic and metastatic potential (21, 23) . These oncogenic properties of IL-8 are consistent with our result. Our findings raised the possibility that IL-8 may be a useful biomarker for the response to chemotherapy in patients with PC, although the sample size in the present study was relatively small. To date, no predictive biomarker for the response to chemotherapy in patients with PC exists; therefore, a prospective study is needed. Meanwhile, plasma IL-8 levels in CC patients without and with metastasis were 56.0 + 38.6 and 108.3 + 90.1 pg/ml, respectively, and the mean level with metastasis was higher than that without metastasis. However, the correlation did not achieve statistical significance (P ¼ 0.297), because the sample size of patients with metastasis was too small (four cases) to conclude.
In conclusion, we evaluated the plasma levels of angiogenesis-related molecules using the antibody suspension bead arrays system and found that the levels of these molecules basically were not increased in PC patients, compared with patients with CC or benign diseases. Our results raised the possibility that the IL-8 level may be a biomarker for the response to chemotherapy in PC patients.
Supplementary data
Supplementary data are available at http:// www.jjco.oxfordjournals.org. Figure 3 . Kaplan -Meier curves for progression-free survival (A) and overall survival (B) according to the plasma IL-8 level in pancreatic cancer patients who received chemotherapy. The median value was used as the cut-off value. High IL-8, pancreatic cancer patients whose plasma IL-8 level was .29.0 pg/ ml. Low IL-8, those whose plasma IL-8 level was ,29.0 pg/ml. The difference was evaluated using the log-rank test.
